TY - JOUR
T1 - A novel pharmacological entity toward integrated multimodal immunotherapy
AU - Sirera, Rafael
AU - Beltrán-Visiedo, Manuel
AU - Galluzzi, Lorenzo
N1 - Copyright © 2024 Elsevier Ltd. All rights reserved.
PY - 2025/2
Y1 - 2025/2
N2 - Most solid tumors are insensitive to single-agent immunotherapy, calling for the development of combinatorial treatment regimens. Recently, Lin and collaborators developed a pharmacological platform enabling the combination of different immunotherapies into a single chemical entity. This approach may effectively circumvent obstacles associated with the simultaneous delivery of multiple immunotherapeutic agents.
AB - Most solid tumors are insensitive to single-agent immunotherapy, calling for the development of combinatorial treatment regimens. Recently, Lin and collaborators developed a pharmacological platform enabling the combination of different immunotherapies into a single chemical entity. This approach may effectively circumvent obstacles associated with the simultaneous delivery of multiple immunotherapeutic agents.
KW - CD8 cytotoxic T lymphocyte
KW - dendritic cell
KW - immune checkpoint inhibitor
KW - immunoevasion
KW - multimodal targeting chimera
KW - triple orthogonal linker
KW - Neoplasms/therapy
KW - Animals
KW - Immunotherapy/methods
KW - Humans
KW - Combined Modality Therapy
UR - http://www.scopus.com/inward/record.url?scp=85212980765&partnerID=8YFLogxK
U2 - 10.1016/j.tips.2024.12.001
DO - 10.1016/j.tips.2024.12.001
M3 - Review article
C2 - 39721827
AN - SCOPUS:85212980765
SN - 0165-6147
VL - 46
SP - 95
EP - 97
JO - Trends in Pharmacological Sciences
JF - Trends in Pharmacological Sciences
IS - 2
ER -